You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Ramipril improves walking times and quality of life in patients with stable intermittent claudication
  1. Julie Brittenden
  1. Division of Applied Medicine, University of Aberdeen, Aberdeen, UK
  1. Correspondence to: Professor Julie Brittenden, Division of Applied Medicine, University of Aberdeen, Polwarth Building, Room 4016, Foresterhill, Aberdeen AB12 2ZN, UK; j.brittenden{at}abdn.ac.uk

https://doi.org/10.1136/eb-2013-101301

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Ahimastos AA, Walker PJ, Askew C, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013;309:453–60.OpenUrlCrossRefPubMedWeb of Science

    Context

    Intermittent claudication (IC) is a common condition that may be associated with significant disability and reduction in quality of life. Pharmacological options for the treatment of the symptoms of this condition are very limited. Naftidrofuryl oxalate is recommended in the National Institute for Health and Care Excellence (NICE) guidelines,1 and while this has been shown to improve pain-free and maximal walking distances, its effect, if any, on quality of life is unknown. ACE inhibitors (ACEI) are believed to have the potential to improve blood flow, endothelial function, and alter muscle metabolism and structure. Previous small studies involving ACEI have shown …

    View Full Text

    Footnotes

    • Competing interests None.